OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

Plain-language summary

This study examines analysis of circulating free DNA in plasma to help guide anti-EGFR treatment in patients with metastatic colorectal cancer. Adults aged 18 and older with histopathologically confirmed metastatic colorectal cancer who were suitable for standard anti-EGFR monoclonal antibody therapy were able to take part. This was a phase-not-applicable study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Karen-Lise Garm Spindler

Intervention

Plasma circulating DNA analysis

Start date

6/1/2018

Estimated completion

12/31/2022

Countries

Denmark

Related genes

Locations

• Aarhus, Denmark

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion criteria

* Histopathologically verified metastatic colorectal cancer
* Indication for systemic palliative treatment with standard Anti-EGFR monoclonal antibodies
* Fit for therapy with EGFR inhibition
* Consent to treatment and sampling
* Measureable disease according to RECIST v 1.1
* Age ≥ 18

Exclusion criteria

* PS \> 2
* Significant other cancer disease within 5 years of inclusion
* Conditions precluding sampling during therapy and treatment breaks.